一套把基础发现推向临床的转化架构:底层硬件采集、中层 AI 解码、顶层药效评价——从实验台(Bench),经技术桥(Bridge),到床旁(Bedside)。目标是重大脑疾病的靶向干预。 A translational architecture that pushes discovery toward the clinic: hardware acquisition at the base, AI decoding in the middle, efficacy evaluation on top — from Bench, across the Bridge, to Bedside. The target: precision intervention for major brain disorders.
硬件负责"感知与调控",AI 负责"解码与建模",顶层负责"表型与药效"——三层叠起来,就是一条从信号到新药的完整流水线。 Hardware senses and modulates, AI decodes and models, and the top layer evaluates phenotype and efficacy — stacked together, a full pipeline from signal to new therapeutics.
动物情感与社交行为学范式库,针对抑郁症、自闭症、AD 高效筛选新药。Animal affect & social-behavior paradigm library — high-throughput screening for depression, autism, and AD therapeutics.
引入多组学与海量神经电生理信号的 AI 建模,构建脑机接口雏形算法。AI modeling over multi-omics and large-scale electrophysiology — the algorithmic seed of a brain-machine interface.
高精度"在体记录 - 光遗传调控 - 神经肽微流控检测芯片"复合硬件平台。High-precision composite platform: in vivo recording, optogenetic control, and neuropeptide microfluidic detection chips.
生物学机制层(The Bench)输出机制,技术转化平台(The Bridge)承接落地,临床应用场景(The Bedside)对接真实患者——一条自上而下贯通的路径。 The Bench produces mechanism, the Bridge carries it into technology, and the Bedside meets real patients — one continuous top-to-bottom path.
在体读出技术平台与微环路靶点机制两股力量收束,导向三个高价值方向:AD 新视野、数字药物与无创干预、前沿支撑平台。 The in vivo readout platform and microcircuit-target mechanisms converge into three high-value directions: a new lens on AD, digital & non-invasive therapeutics, and enabling frontier platforms.
阻断"社会孤独导致免疫失调"的恶性循环。Breaking the vicious cycle where social isolation drives immune dysregulation.
基于社交缓冲机制的新型干预。Novel intervention built on the social-buffering mechanism.
基于触觉靶点与微环路的精准调控。Precision modulation via tactile targets and microcircuits.
深部脑刺激(DBS)的转化型联合项目。Translational deep-brain-stimulation (DBS) project.